pI: 8.2486 |
Length (AA): 831 |
MW (Da): 93320 |
Paralog Number:
4
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 7 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 823 | 1kk8 (A) | 6 | 825 | 30.00 | 0 | 1 | 1.23 | -0.67 |
16 | 778 | 1g8x (A) | 17 | 764 | 31.00 | 0 | 1 | 1.36 | -0.97 |
38 | 773 | 1br2 (A) | 35 | 789 | 30.00 | 0 | 1 | 1.18 | -1.21 |
5 | 825 | 4qbd (A) | 5 | 803 | 28.00 | 0 | 1 | 1.27207 | 0.06 |
6 | 821 | 3i5g (A) | 2 | 825 | 30.00 | 0 | 1 | 1.32805 | 0.04 |
100 | 778 | 1lkx (C) | 9 | 697 | 29.00 | 0 | 1 | 1.21819 | -0.41 |
103 | 761 | 5hmp (A) | 71 | 741 | 36.00 | 0 | 1 | 1.21322 | -0.37 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite, ME49 Oocyst, ME49 Bradyzoite. | Gregory Hehl AB Fritz HM Sibley/Greg |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Gregory | ToxoDB |
Ortholog group members (OG5_126672)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_IV012030 | myosin B |
Babesia bovis | BBOV_I003490 | myosin A |
Candida albicans | CaO19.8357 | myosin type 1 |
Candida albicans | CaO19.738 | myosin type 1 |
Caenorhabditis elegans | CELE_F29D10.4 | Protein HUM-1 |
Caenorhabditis elegans | CELE_T02C12.1 | Protein HUM-5 |
Cryptosporidium hominis | Chro.70423 | unconventional myosin-A |
Cryptosporidium hominis | Chro.70483 | myosin B |
Cryptosporidium parvum | cgd7_3790 | unconventional myosin |
Cryptosporidium parvum | cgd7_4350 | myosinunconventional myosin fused to an RCC1 domain (unique) |
Dictyostelium discoideum | DDB_G0276617 | class I myosin |
Dictyostelium discoideum | DDB_G0289117 | class I myosin |
Dictyostelium discoideum | DDB_G0275447 | class I myosin |
Dictyostelium discoideum | DDB_G0289177 | class I myosin |
Dictyostelium discoideum | DDB_G0288679 | class I myosin |
Dictyostelium discoideum | DDB_G0280039 | class I myosin |
Drosophila melanogaster | Dmel_CG7438 | Myosin 31DF |
Drosophila melanogaster | Dmel_CG5501 | Myosin 95E |
Drosophila melanogaster | Dmel_CG9155 | Myosin 61F |
Entamoeba histolytica | EHI_110810 | unconventional myosin IB |
Homo sapiens | ENSG00000142347 | myosin IF |
Homo sapiens | 4643 | myosin IE |
Homo sapiens | ENSG00000166866 | myosin IA |
Homo sapiens | ENSG00000174527 | myosin IH |
Homo sapiens | ENSG00000136286 | myosin IG |
Homo sapiens | ENSG00000176658 | myosin ID |
Homo sapiens | ENSG00000197879 | myosin IC |
Homo sapiens | ENSG00000128641 | myosin IB |
Leishmania braziliensis | LbrM.20.0970 | myosin IB heavy chain, putative |
Leishmania donovani | LdBPK_341070.1 | myosin IB heavy chain, putative |
Leishmania infantum | LinJ.34.1070 | myosin IB heavy chain, putative |
Leishmania major | LmjF.34.1000 | myosin IB heavy chain, putative |
Leishmania mexicana | LmxM.33.1000 | myosin IB heavy chain, putative |
Loa Loa (eye worm) | LOAG_06763 | hypothetical protein |
Mus musculus | ENSMUSG00000066952 | myosin 1H |
Mus musculus | ENSMUSG00000018417 | myosin IB |
Mus musculus | ENSMUSG00000032220 | myosin IE |
Mus musculus | ENSMUSG00000017774 | myosin IC |
Mus musculus | ENSMUSG00000035441 | myosin ID |
Mus musculus | ENSMUSG00000020437 | myosin IG |
Mus musculus | ENSMUSG00000025401 | myosin IA |
Mus musculus | ENSMUSG00000024300 | myosin IF |
Neospora caninum | NCLIV_028750 | hypothetical protein |
Neospora caninum | NCLIV_049900 | hypothetical protein |
Neospora caninum | NCLIV_024740 | Myosin, heavy polypeptide 1, skeletal muscle, adult, related |
Neospora caninum | NCLIV_018020 | hypothetical protein |
Neospora caninum | NCLIV_016180 | hypothetical protein |
Plasmodium berghei | PBANKA_1355700 | myosin A |
Plasmodium falciparum | PF3D7_1342600 | myosin A |
Plasmodium knowlesi | PKNH_1258800 | myosin A, putative |
Plasmodium vivax | PVX_083030 | myosin A, putative |
Plasmodium yoelii | PY01232 | myosin A |
Saccharomyces cerevisiae | YKL129C | myosin 3 |
Saccharomyces cerevisiae | YMR109W | myosin 5 |
Schmidtea mediterranea | mk4.000662.04 | |
Schmidtea mediterranea | mk4.013048.00 | Myosin-IB |
Schmidtea mediterranea | mk4.000086.00 | |
Schmidtea mediterranea | mk4.006357.03 | |
Schmidtea mediterranea | mk4.005104.00 | Hum-1 |
Trypanosoma brucei gambiense | Tbg972.4.3390 | myosin IB heavy chain, putative |
Trypanosoma brucei | Tb927.4.3380 | myosin IB heavy chain, putative |
Trypanosoma congolense | TcIL3000_4_3080 | myosin IB heavy chain, putative |
Trypanosoma cruzi | TcCLB.507739.110 | myosin IB heavy chain, putative |
Toxoplasma gondii | TGME49_243250 | myosin H |
Toxoplasma gondii | TGME49_239560 | myosin E |
Toxoplasma gondii | TGME49_263180 | myosin D |
Toxoplasma gondii | TGME49_255190 | myosin C |
Toxoplasma gondii | TGME49_235470 | myosin A |
Theileria parva | TP01_0500 | myosin A, putative |
Theileria parva | TP01_1107 | myosin B, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.3380 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.3380 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.3380 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.3380 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1355700 | Plasmodium berghei | Essential | plasmo |
TGME49_255190 | Toxoplasma gondii | Probably essential | sidik |
TGME49_235470 this record | Toxoplasma gondii | Probably essential | sidik |
TGME49_239560 | Toxoplasma gondii | Probably essential | sidik |
TGME49_243250 | Toxoplasma gondii | Probably essential | sidik |
TGME49_263180 | Toxoplasma gondii | Probably essential | sidik |
TGME49_255190 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_235470 this record | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_239560 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_243250 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_263180 | Toxoplasma gondii | Probably non-essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.